Mga Batayang Estadistika
| LEI | 5493001OUCRYIW3XQZ24 |
| CIK | 1634432 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Strongbridge Biopharma plc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 11, 2022 |
SBBP / Strongbridge Biopharma plc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. |
|
| February 11, 2022 |
CUSIP No. G85347105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.01 per share, of Strongbridge Biopharma plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| January 5, 2022 |
SBBP / Strongbridge Biopharma plc / CAXTON CORP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G85347105 (CUSIP Number) Mr. Heath N. Weisberg Caxton Corporation 731 Alexander Road, Bldg. 2, Suite 500 Princeton, New Jersey 08540 (212) 205-6805 (Name, Addres |
|
| October 25, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $.01 par value (Title of Class of Securities) G85347105 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 8 |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37569 STRONGBRIDGE BIOPHARMA PLC (Exact name of registrant as specified |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 S-8 POS 1 tm2127087d7s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. 333-215532 Registration No. 333-222818 Registration No. 333-225319 Registration No. 333-230931 Registration No. 333-236911 Registration No. 333-255286 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGIST |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 5, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (Com |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. Exhibit 99.1 Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., October 5, 2021 ? Strongbridge Biopharma plc (NASDAQ: SBBP) (the ?Company? or ?Strongbridge?) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 S-8 POS 1 tm2127087d11s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. 333-215532 Registration No. 333-222818 Registration No. 333-225319 Registration No. 333-230931 Registration No. 333-236911 Registration No. 333-255286 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGIS |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| October 5, 2021 |
As filed with the Securities and Exchange Commission on October 5, 2021 As filed with the Securities and Exchange Commission on October 5, 2021 Registration No. |
|
| September 13, 2021 |
Filed by Xeris Pharmaceuticals, Inc. 425 Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: September 13, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbr |
|
| September 8, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., September 8, 2021 ? Strongbridge Biopharma plc (NASDAQ: SBBP) (the ?Company? or ?Strongbridge?) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceutica |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (C |
|
| August 31, 2021 |
Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc S-4 Commission File No.: 333-257642 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biophar |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 30, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (Com |
|
| August 30, 2021 |
425 Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: August 30, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbridg |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 30, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (Com |
|
| August 30, 2021 |
Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc S-4 Commission File No.: 333-257642 Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Sharehol |
|
| August 30, 2021 |
Filed by Xeris Pharmaceuticals, Inc. 425 Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: August 30, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbridg |
|
| August 26, 2021 |
Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) 425 1 tm2123834d3425.htm 425 Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc S-4 Commission File No.: 333-257642 Email from Strongbridge’s Chief Financial Officer and Chief E |
|
| August 26, 2021 |
Filed by Xeris Pharmaceuticals, Inc. Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: August 26, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbridge Bi |
|
| August 12, 2021 |
Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc S-4 Commission File No.: 333-257642 Form of Email to Strongbridge Shareholders Good morning [?], I hope this email finds you d |
|
| August 6, 2021 |
Filed by Xeris Pharmaceuticals, Inc. Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: August 6, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbridge Biopharma plc by Xeris Phar |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
Exhibit 99.1 ? ? Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update ? ~ Reports KEVEYIS? (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~ ? ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top End of Full-Year 2021 KEVEYIS |
|
| August 5, 2021 |
425 1 sbbp-20210805x425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdict |
|
| August 5, 2021 |
Exhibit 99.1 ? ? Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update ? ~ Reports KEVEYIS? (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~ ? ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top End of Full-Year 2021 KEVEYIS |
|
| August 2, 2021 |
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement Filed by Strongbridge Biopharma plc (Commission File No.: 001-37569) Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc S-4 Commission File No.: 333-257642 Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement DUBLIN, Ir |
|
| July 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| July 26, 2021 |
Exhibit 2.1 FIRST AMENDMENT TO TERM LOAN AGREEMENT This FIRST AMENDMENT TO TERM LOAN AGREEMENT, dated as of July 23, 2021 (this ?Amendment?), is entered into by and among Strongbridge U.S. Inc., a Delaware corporation (the ?Borrower?), Strongbridge Biopharma plc, a public limited company incorporated under the laws of Ireland (the ?Parent Guarantor?), each Lender party hereto designated as a ?Lend |
|
| July 26, 2021 |
Exhibit 2.2 Lock-Up Agreement July 23, 2021 Avenue Venture Opportunities Fund, L.P., in its capacity as a Lender under the Existing Credit Agreement referred to below 11 W. 42nd St., 9th Floor New York, NY 10036 Ladies and Gentlemen: This Lock-Up Agreement is being delivered to you in connection with the proposed First Amendment to Term Loan Agreement (the ?Amendment?), entered into among Strongbr |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation or organizat |
|
| July 26, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 ? Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with signifi |
|
| July 26, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation or organizat |
|
| July 9, 2021 |
SBBP / Strongbridge Biopharma plc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) July 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (Commis |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 001-37569 (Commis |
|
| June 25, 2021 |
June 25, 2021 By EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-4561 Attention: Jenn Do and Kevin Vaughn Re: Strongbridge Biopharma plc Form 10-K for the fiscal year ended December 31, 2020 Filed March 3, 2021 File No. |
|
| May 25, 2021 |
Filed by Xeris Pharmaceuticals, Inc. Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: May 24, 2021 The following communication is a transcript of a conference call held on May 24, 2021 and is being filed in connection with the prop |
|
| May 24, 2021 |
Xeris to Acquire Strongbridge Creating an Innovative Leader in Endocrinology and Rare Diseases May 24, 2021 Exhibit 99. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation or organizati |
|
| May 24, 2021 |
Strongbridge Transaction Patient Letter Exhibit 99.7 Strongbridge Transaction Patient Letter Dear [Valued Patient / INSERT CUSTOMARY GREETING], I am pleased to share some exciting news about the future of Strongbridge. This morning, we announced that Xeris Pharmaceuticals will acquire Strongbridge to create an innovative leader in endocrinology and rare diseases. As you know, at Strongbridge we are driven by our mission to build a stron |
|
| May 24, 2021 |
Exhibit 2.1 DATED MAY 24, 2021 STRONGBRIDGE BIOPHARMA PLC, XERIS PHARMACEUTICALS, INC., XERIS BIOPHARMA HOLDINGS, INC. AND WELLS MERGERSUB, INC. TRANSACTION AGREEMENT CONTENTS 1. INTERPRETATION 1 1.1??Definitions 1 1.2??Construction 20 1.3??Captions 20 1.4??Time 21 2. RULE 2.5 ANNOUNCEMENT, SCHEME DOCUMENT AND STRONGBRIDGE RULE 15 PROPOSALS 21 2.1??Rule 2.5 Announcement 21 2.2??Scheme 22 2.3??Chan |
|
| May 24, 2021 |
Form of Irrevocable Undertaking. Exhibit 10.1 DEED OF IRREVOCABLE UNDERTAKING To: Xeris Pharmaceuticals, Inc. (?Xeris?) Xeris Biopharma Holdings, Inc. (?Holdco?) [ ] May 2021 Dear Sirs PROPOSED ACQUISITION OF STRONGBRIDGE BY HOLDCO, AN AFFILIATED COMPANY OF XERIS I refer to the proposed acquisition of Strongbridge Biopharma plc (the ?Company?) by Holdco, a newly incorporated company and affiliate of Xeris. Under the proposed tran |
|
| May 24, 2021 |
Exhibit 99.2 XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near-term Inflection Points Diversifies Revenue Base with Two Rapidly Growing Brands in Xeris? Gv |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation or organizati |
|
| May 24, 2021 |
Filed by Xeris Pharmaceuticals, Inc. Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: May 24, 2021 The following communication is being filed in connection with the proposed acquisition of Strongbridge Biopharma plc by Xeris Pharma |
|
| May 24, 2021 |
Strongbridge Transaction Employee Letter Exhibit 99.5 Strongbridge Transaction Employee Letter **Confidential ? For Internal Strongbridge Biopharma Use Only** Dear Colleagues, Today is an exciting day for Strongbridge and I wanted to share our news with you personally. Moments ago, we announced Xeris Pharmaceuticals will acquire Strongbridge in a transaction that values Strongbridge at approximately $267 million. This combination marks a |
|
| May 24, 2021 |
Strongbridge Transaction Partner / Vendor Letter Exhibit 99.8 Strongbridge Transaction Partner / Vendor Letter Dear [Valued Partner / INSERT CUSTOMARY GREETING], I am pleased to share some exciting news about the future of Strongbridge. Today, we announced that Xeris Pharmaceuticals will acquire Strongbridge to create an innovative leader in endocrinology and rare diseases. We are taking this step because it will provide us with an opportunity t |
|
| May 24, 2021 |
Strongbridge Transaction Physician / KOL / Patient Advocacy Group Letter Exhibit 99.6 Strongbridge Transaction Physician / KOL / Patient Advocacy Group Letter **Confidential ? For Internal Strongbridge Biopharma Use Only** Dear INSERT, I wanted to reach out to you directly to share some exciting news about the future of Strongbridge given your very important role as [a/an advocacy leader, healthcare practitioner, investigator]. Today, we announced that Xeris Pharmaceut |
|
| May 24, 2021 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.5 OF THE IRISH TAKEOVER RULES FOR IMMEDIATE RELEASE XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR |
|
| May 24, 2021 |
Exhibit 2.3 EXECUTION VERSION Dated May 24, 2021 XERIS PHARMACEUTICALS, INC. STRONGBRIDGE BIOPHARMA PLC EXPENSES REIMBURSEMENT AGREEMENT TABLE OF CONTENTS 1 Definitions 1 2 Pre-condition 6 3 Xeris reimbursement 6 4 General 8 EXPENSES REIMBURSEMENT AGREEMENT THIS EXPENSES REIMBURSEMENT AGREEMENT (this Agreement), dated as of May 24, 2021 and made between: (1) XERIS PHARMACEUTICALS, INC., a Delaware |
|
| May 24, 2021 |
Filed by Xeris Pharmaceuticals, Inc. Filed by Xeris Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Strongbridge Biopharma plc Commission File No.: 001-37569 Date: May 24, 2021 Xeris Pharmaceuticals, Inc. (?Xeris?) is using or making available the following communications through the website www.xerisstrongb |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 XERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38536 20-3352427 (State or other jurisdiction of incorporation) (Commissio |
|
| May 24, 2021 |
Appendix III to the Rule 2.5 Announcement (Conditions Appendix). Exhibit 2.2 APPENDIX III CONDITIONS OF THE ACQUISITION AND THE SCHEME The Acquisition and the Scheme will comply with the Takeover Rules, the Act and, where relevant, the rules and regulations of the Exchange Act and Nasdaq, and are subject to the terms and conditions set out in this announcement and to be set out in the Scheme Document. The Acquisition and the Scheme are, to the extent required b |
|
| May 24, 2021 |
Exhibit 99.4 The announcement issued jointly by Xeris and Strongbridge under Rule 2.5 of the Irish Takeover Rules on May 24, 2021 (the ?Rule 2.5 Announcement?) is available on Xeris? website at www.xerispharma.com and on Strongbridge?s website at www.strongbridgebio.com. Appendix I to the Rule 2.5 Announcement contains further details of the sources of information and bases of calculations set out |
|
| May 24, 2021 |
Filed by Strongbridge Biopharma plc Filed by Strongbridge Biopharma plc Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Strongbridge Biopharma plc Commission File No. |
|
| May 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 13, 2021 |
Exhibit 99.1 ? Strongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV? (levoketoconazole) for the Treatment of Endogenous Cushing?s Syndrome ? ~ FDA Sets Prescription Drug User Fee Act (PDUFA) Target Action Date of January 1, 2022 ~ ? ~ If Approved, RECORLEV? (levoketoconazole) Launch Planned for First Quarter of 2022 |
|
| May 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2021 |
Exhibit 99.1 ? ? Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update ? ~ Reports KEVEYIS? (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ? ~ Reiterates Full-Year 2021 KEVEYIS? (dichlorphenamide) Revenue Guidance of Approximately $34 Million to $ |
|
| April 16, 2021 |
As filed with the Securities and Exchange Commission on April 16, 2021 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defini |
|
| March 30, 2021 |
CORRESP 1 filename1.htm 900 Northbrook Drive Suite 200 Trevose, PA 19053 (610) 254-9022 March 31, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Jane Park Re: Strongbridge Biopharma plc – Request for Acceleration Registration Statement on Form S-3 File No. 333- 254733 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under th |
|
| March 26, 2021 |
Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM March 25, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Strongbridge Biopharma plc, an Irish public limited company (registered no. 562659) (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or pri |
|
| March 26, 2021 |
Registration Statement on Form S-3 (No. 333-254733), filed with the SEC on March 26, 2021. As filed with the Securities and Exchange Commission on March 25, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Strongbridge Biopharma plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation or organization) 2834 (Primary St |
|
| March 26, 2021 |
Form of Subordinated Indenture Exhibit 4.5 STRONGBRIDGE BIOPHARMA PLC and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3 |
|
| March 26, 2021 |
Exhibit 4.4 STRONGBRIDGE BIOPHARMA PLC and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commissio |
|
| March 3, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update ~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide) Full-Year 2020 Revenue of $30.7 Million, a 41.5 Percent Increase over 2019 Reven |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2021 |
Subsidiaries of Strongbridge Biopharma plc Exhibit 21.1 Subsidiaries of the Company Strongbridge U.S. Inc. (a Delaware corporation) Strongbridge Dublin Limited (a private limited company incorporated under the laws of Ireland) Cortendo AB (a private limited company incorporated under the laws of Sweden) |
|
| March 3, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commission |
|
| March 2, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration ~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commis |
|
| February 16, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Promotion of Richard S. Kollender to President and Chief Financial Officer DUBLIN, Ireland and TREVOSE, Pa., February 16, 2021 — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* STRONGBRIDGE BIOPHARMA plc (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 12, 2021 |
CUSIP No. G85347105 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Strongbridge Biopharma plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Strongbridge Biopharma plc (Name of Issuer) Common Stock, $0. |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 3, 2021 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., February 3, 2021 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awa |
|
| February 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commiss |
|
| January 6, 2021 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update ~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~ ~ Targets Full-Year 2021 KEV |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commissi |
|
| November 23, 2020 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) Strongbridge Biopharma plc (Name of Issuer) Common Stock (Title of Class of Securities) G85347105 (CUSIP Number) November 23, 2020 (Date of Event Which Requires |
|
| October 29, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate Update ~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study in the Third Quarter of 2020 ~ ~ Reports KEVEYIS® (dichlorphenamide) Third Quarter 2 |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commiss |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 |
|
| September 23, 2020 |
SBBP / Strongbridge Biopharma plc / CAXTON CORP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G85347105 (CUSIP Number) Mr. Heath N. Weisberg Caxton Corporation 731 Alexander Road, Bldg. 2, Suite 500 Princeton, New Jersey 08540 (212) 205-6805 (Name, Addres |
|
| September 18, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commi |
|
| September 18, 2020 |
Exhibit 1.1 11,111,111 Ordinary Shares Strongbridge Biopharma plc UNDERWRITING AGREEMENT September 16, 2020 JEFFERIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 7th Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Introduct |
|
| September 18, 2020 |
Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares Exhibit 99.1 Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares Dublin, Ireland and Trevose, Pa., September 16, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it intends to offer and |
|
| September 18, 2020 |
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares Exhibit 99.2 Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares Dublin, Ireland and Trevose, Pa., September 16, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has priced its prev |
|
| September 18, 2020 |
PROSPECTUS SUPPLEMENT (To Prospectus dated March 27, 2018) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223575 PROSPECTUS SUPPLEMENT (To Prospectus dated March 27, 2018) 11,111,111 Shares Ordinary Shares We are offering 11,111,111 of our ordinary shares. Our ordinary shares are listed on The Nasdaq Global Select Market under the symbol "SBBP." On September 15, 2020, the last reported sale price of our ordinary shares on The Nasd |
|
| September 16, 2020 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223575 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is |
|
| September 8, 2020 |
Exhibit 99.2 Strongbridge Biopharma plc Provides Corporate Update ~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To View the Complete Earlier Announcement, Visit the Company’s Website ~ ~ Company Anticipates Submitting a New Drug Application (NDA) fo |
|
| September 8, 2020 |
Exhibit 99.3 STRONGBRIDGE BIOPHARMA PLC SEPTEMBER 2020 Forward-looking statements This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitati |
|
| September 8, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome ~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Pati |
|
| September 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update ~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~ ~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketoconazole) in Endogenous C |
|
| August 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 Stro |
|
| August 4, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between Strongbridge U.S. Inc., a Delaware corporation (the “Company”), and John Johnson (“Executive”) as of July 2, 2020 (the "Effective Date"). W I T N E S S E T H: WHEREAS, the Company and Executive are parties to that certain Executive Chairman Agreement, dated as of November 1, 2019 (such agreement, t |
|
| August 4, 2020 |
Exhibit 10.2 TERM LOAN AGREEMENT, dated as of May 19, 2020, among STRONGBRIDGE U.S. INC., as Borrower STRONGBRIDGE BIOPHARMA PLC, CORTENDO AB (PUBL), STRONGBRIDGE DUBLIN LIMITED, as Guarantors, The other Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and AVENUE VENTURE OPPORTUNITIES FUND, L.P., as Administrative Agent and Collateral Agent U.S. $30 |
|
| August 4, 2020 |
Exhibit 10.3 WARRANT THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQU |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| July 7, 2020 |
Strongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive Officer Exhibit 99.1 Strongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive Officer Dublin, Ireland and Trevose, Pa., July 7, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that at the request o |
|
| May 20, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. Dublin, Ireland and Trevose, Pa., May 20, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it |
|
| May 20, 2020 |
/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| May 14, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 11, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome ~ Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 ~ Dublin, Ireland and Trevose, Pa., May 11, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company fo |
|
| May 6, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Reports First Quarter 2020 Financial Results and Provides Corporate Update ~ Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) Reaches 41 of 42 Targeted Study Participants Completing the Randomized Withdrawal Phase; One Additional Patient Currently in the Randomized Withdrawal Phase and One Other Patient Scheduled to be Randomized Imminently ~ ~ LOGICS En |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number) |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 Str |
|
| April 20, 2020 |
SBBP / Strongbridge Biopharma plc DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defini |
|
| April 10, 2020 |
Amendment to Executive Chairman Agreement. Exhibit 10.1 STRONGBRIDGE U.S. INC. AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT This Amendment (“Amendment”) to the Executive Chairman Agreement between Strongbridge Biopharma plc (“Strongbridge”), Strongbridge U.S. Inc., a Delaware corporation (the “Company”), and John Johnson (the “Executive”) dated November 1, 2020 (the “Agreement”) is made and entered into as of April 8, 2020 (the “Effective Dat |
|
| April 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numbe |
|
| April 1, 2020 |
Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 1, 2020; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defini |
|
| March 19, 2020 |
G85347105 / Strongbridge Biopharma PLC / Ikarian Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* STRONGBRIDGE BIOPHARMA plc (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) March 9, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| March 19, 2020 |
JOINT FILING AGREEMENT March 19, 2020 EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT March 19, 2020 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includ |
|
| March 17, 2020 |
SBBP / Strongbridge Biopharma plc PRE 14A - - PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 5, 2020 |
Form S-8 filed with the SEC on March 5, 2020 (File No. 333-236911) As filed with the Securities and Exchange Commission on March 5, 2020 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2020 |
Description of Ordinary Shares Exhibit 4.1 STRONGBRIDGE BIOPHARMA PLC DESCRIPTION OF ORDINARY SHARES Strongbridge Biopharma plc (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) – ordinary shares, par value $0.01 per share (the “Ordinary Shares”). The Ordinary Shares trade on The Nasdaq Global Select Market under the trading symbol “SB |
|
| February 28, 2020 |
Exhibit 10.16 STRONGBRIDGE BIOPHARMA PLC NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD Strongbridge Biopharma plc (the “Company”) has determined to grant to you an award of restricted stock units (the “RSUs”) under the Non-Employee Director Equity Compensation Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement |
|
| February 28, 2020 |
SBBP / Strongbridge Biopharma plc 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| February 28, 2020 |
Exhibit 10.26 STRONGBRIDGE BIOPHARMA PLC AMENDMENT TO OPTION AWARD AGREEMENTS This AMENDMENT TO OPTION AWARD AGREEMENTS (this “Agreement”) dated as of November 26, 2019, is entered into by and between Strongbridge Biopharma plc (the “Company”) and Matthew Pauls (the “Grantee”). The Grantee has previously received grants of restricted stock units and stock options under the Strongbridge Biopharma p |
|
| February 28, 2020 |
Exhibit 10.25 STRONGBRIDGE U.S. INC. EXECUTIVE CHAIRMAN AGREEMENT This Executive Chairman Agreement (the “Agreement”) is made and entered into as of November 1, 2019 (the “Effective Date”), between Strongbridge Biopharma plc (“Strongbridge”), Strongbridge U.S. Inc., a Delaware corporation (the “Company”), and John Johnson (the “Executive”). WHEREAS, the Executive currently serves as a non-executiv |
|
| February 28, 2020 |
Subsidiaries of Strongbridge Biopharma plc Exhibit 21.1 Subsidiaries of the Company Strongbridge U.S. Inc. (a Delaware corporation) Strongbridge Dublin Limited (a private limited company incorporated under the laws of Ireland) Cortendo AB (publ) (a public limited liability company incorporated under the laws of Sweden) |
|
| February 28, 2020 |
Form of Indemnification Agreement FORM OF INDEMNIFICATION AGREEMENT Exhibit 10.8 Dated Strongbridge Biopharma public limited company and [] DEED OF INDEMNIFICATION AGREEMENT THIS DEED OF INDEMNIFICATION (this “Agreement”), dated as of [], is made by and between Strongbridge Biopharma public limited company, an Irish public limited company (“Strongbridge”) and [] (the “Indemnitee”). WHEREAS, the Company and Indemnitee intend for th |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| February 25, 2020 |
BIOPHARMA PLC STRONGBRIDGE FEBRUARY 2020 Exhibit 99.1 BIOPHARMA PLC STRONGBRIDGE FEBRUARY 2020 Forward-looking statements This document contains forward-looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company’s future financial pos |
|
| February 25, 2020 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update ~ KEVEYIS®(dichlorphenamide) Full-Year 2019 Revenue of $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Full-Year 2020 KEVEYIS®(dichlorphenamide) Revenue Guidance of Approximately $26 to $27 Million; Company Anticipates Continued Positive and |
|
| February 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| February 14, 2020 |
SBBP / Strongbridge Biopharma plc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
SBBP / Strongbridge Biopharma plc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2020 |
SBBP / Strongbridge Biopharma plc / HealthCap VI, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 30, 2020 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., January 30, 2020 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awa |
|
| January 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Nu |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Num |
|
| January 9, 2020 |
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities ~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5. |
|
| November 19, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc November 2019 Forward-looking statements This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company’s future financial pos |
|
| November 19, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| November 18, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| November 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| November 18, 2019 |
Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director ~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide) and Serving the Unmet Needs of the Primary Periodic Paralysis Community ~ Dublin, Ireland and Trevose, Pa. |
|
| November 7, 2019 |
SBBP / Strongbridge Biopharma plc 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 |
|
| November 7, 2019 |
Exhibit 10.1 CONSULTING AGREEMENT This agreement (the “Agreement”) is entered into as of September 3, 2019 (the “Effective Date”) by and between Strongbridge U.S. Inc., having an address at 900 Northbrook Drive, Suite 200, Trevose, PA 19053 (“Company”) and A. Brian Davis, having an address at 504 School House Lane, Willow Grove, PA 19090 (“Consultant”). Consultant and Company agree as follows: 1. |
|
| November 7, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update ~ KEVEYIS® (dichlorphenamide) Achieved $5.7 Million in Revenue Along with a Positive Contribution Margin in Third Quarter of 2019; Strongbridge Remains On-Track to Meet or Exceed the Top End of Full-Year KEVEYIS Revenue Guidance of $18 Million to $20 Million ~ ~ Phase 3 LOGICS Study o |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Nu |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Nu |
|
| November 5, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Announces CEO Transition Plan and Provides Preliminary Third Quarter 2019 Financial Results and Corporate Updates Dublin, Ireland and Trevose, Pa., November 5, 2019 — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant |
|
| August 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| August 13, 2019 |
Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth ~ Richard S. |
|
| July 31, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update ~ KEVEYIS® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV™ (levoketoconazole) Progressing with Top-Line Data Anticipated at |
|
| July 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numbe |
|
| July 31, 2019 |
SBBP / Strongbridge Biopharma plc 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 Stro |
|
| July 19, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numbe |
|
| July 19, 2019 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., July 19, 2019 – Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards |
|
| May 16, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland 001-37569 98-1275166 (State or other (Commission (I.R.S. Employer jurisdiction of |
|
| May 1, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update ~ Following Type C Meeting with the U.S. Food & Drug Administration (FDA), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of 2020; Submission to Include Data From the Phase 3 SONICS and LOGICS Studies ~ ~ Newly Present |
|
| May 1, 2019 |
SBBP / Strongbridge Biopharma plc 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 |
|
| April 18, 2019 |
Form S-8 filed with the SEC on April 18, 2019 (File No. 333-230931) As filed with the Securities and Exchange Commission on April 18, 2019 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2019 |
SBBP / Strongbridge Biopharma plc DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 11, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| March 11, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome ~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~ ~ Favorable Liver-Related Findings: No Patie |
|
| March 8, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numbe |
|
| March 8, 2019 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., March 8, 2019 — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards |
|
| February 27, 2019 |
Exhibit 10.15 STRONGBRIDGE BIOPHARMA PLC 2017 INDUCEMENT PLAN The purpose of the Strongbridge Biopharma plc 2017 Inducement Plan is to assist Strongbridge Biopharma plc and its affiliates and subsidiaries in attracting valued employees by offering them a greater stake in the Company’s success and a closer identity with it, and to encourage ownership of the Company’s stock by such employees. 1. Def |
|
| February 27, 2019 |
Exhibit 10.14 STRONGBRIDGE BIOPHARMA PLC NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION PLAN The purpose of the Strongbridge Biopharma plc Non-Employee Director Equity Compensation Plan (the “Plan”) is to provide non-employee members of the Board of Directors (the “Board”) of Strongbridge Biopharma plc (the “Company”) with the opportunity to receive grants of nonqualified stock options and stock awards |
|
| February 27, 2019 |
Exhibit 21.1 Subsidiaries of the Company Strongbridge U.S. Inc. (a Delaware corporation) Strongbridge Dublin Limited (a private limited company incorporated under the laws of Ireland) Cortendo AB (publ) (a public limited liability company incorporated under the laws of Sweden) Cortendo Cayman Ltd. (an exempted company incorporated in the Cayman Islands) |
|
| February 27, 2019 |
Exhibit 10.13 STRONGBRIDGE BIOPHARMA PLC 2015 EQUITY COMPENSATION PLAN The purpose of the Strongbridge Biopharma plc 2015 Equity Compensation Plan (the “Plan”) is to provide (i) designated employees of Strongbridge Biopharma plc (the “Company”) and its parents and subsidiaries; (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries; and (iii) non- |
|
| February 27, 2019 |
SBBP / Strongbridge Biopharma plc 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| February 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2019 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File N |
|
| February 26, 2019 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2018 Financial Results ~ RECORLEV™ (levoketoconazole) Phase 3 Clinical Program and Type C FDA Meeting in First Quarter Progressing as Planned ~ ~ $145 Million Upfront Cash Payment and $36.7 Million Equity Investment from Novo Nordisk in Fourth Quarter 2018 Significantly Strengthened Company’s Financial Position Including |
|
| February 14, 2019 |
SBBP / Strongbridge Biopharma plc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 STRONGBRIDGE BIOPHARMA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 14, 2019 |
SBBP / Strongbridge Biopharma plc / Vivo Capital VIII, LLC - SCHEDULE 13G/A Passive Investment Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2019 |
SBBP / Strongbridge Biopharma plc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2019 |
SBBP / Strongbridge Biopharma plc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2019 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value per share (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 1, 2019 |
SBBP / Strongbridge Biopharma plc / HealthCap VI, L.P. - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G85347105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| December 28, 2018 |
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G EX-99.1 CUSIP No. G85347105 SCHEDULE 13G Page 1 3 of 13 Pages EXHIBIT 1 AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G The undersigned hereby agree that the Schedule 13G relating to the common stock of Strongbridge Biopharma plc, and any further amendments thereto, to which this Agreement as to Joint Filing of Schedule 13G is attached as an exhibit is filed on behalf of each of them pursuant to and |
|
| December 28, 2018 |
SBBP / Strongbridge Biopharma plc / Capital Royalty L.p. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value per share (Title of Class of Securities) G85347105 (CUSIP Number) December 18, 2018 (Date of Event W |
|
| December 21, 2018 |
SBBP / Strongbridge Biopharma plc / NOVO NORDISK A S - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value per share (Title of Class of Securities) G85347105 (CUSIP Number) December 18, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2018 STRONGBRIDGE BIOPHARMA plc (Exact Name of Registrant as Specified in Its Charter) Ireland (State or Other Jurisdiction of Incorporation) 001-37569 98-1275166 (Commis |
|
| November 9, 2018 |
SBBP / Strongbridge Biopharma plc / Longitude Capital Partners Iii, Llc - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value per share (Title of Class of Securities) G85347105 (CUSIP Number) October 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 9, 2018 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| October 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2018 STRONGBRIDGE BIOPHARMA plc (Exact Name of Registrant as Specified in Its Charter) Ireland (State or Other Jurisdiction of Incorporation) 001-37569 98-1275166 (Commiss |
|
| October 31, 2018 |
Exhibit 2.1 Execution Version MACRILEN ACQUISITION AGREEMENT dated as of October 31, 2018 between NOVO NORDISK HEALTHCARE AG and STRONGBRIDGE BIOPHARMA PUBLIC LIMITED COMPANY #91416580v21 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Construction 13 Section 1.03. Captions 14 Section 1.04. Time 14 ARTICLE 2 PUT AND CALL OPTIONS 14 Section 2.01. Put Option 14 |
|
| October 31, 2018 |
Exhibit 2.2 Execution Version SHARE PURCHASE AGREEMENT dated as of October 31, 2018 between NOVO NORDISK A/S and STRONGBRIDGE BIOPHARMA PUBLIC LIMITED COMPANY TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Construction 15 Section 1.03. Captions 15 Section 1.04. Time 16 ARTICLE 2 PURCHASE AND SALE Section 2.01. Issuance and Sale 16 Section 2.02. Closing 16 Se |
|
| October 31, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin) ~ Strongbridge to Receive Upfront Payment of $145 Million and Tiered Royalty Stream from Novo Nordisk ~ ~ Novo Nordisk to Purchase Approximately 5.2 Million Ordinary Shares of Strongbridge Biopharma plc at Purchase Price of $7.00 per Share, Resulting in |
|
| October 31, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update ~ Financial Position to be Significantly Strengthened in Fourth Quarter 2018 by $145 Million of Upfront Cash and $36.7 Million Equity Investment from Separately Announced Transactions with Novo Nordisk; Company Intends to Utilize Portion of Proceeds to Repay Outstanding Debt of $88 Mi |
|
| October 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Nu |
|
| October 31, 2018 |
SBBP / Strongbridge Biopharma plc 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-3 |
|
| October 22, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Nu |
|
| October 22, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association ~ As Previously Reported, SONICS Met its Primary Endpoint With 30 Percent of the ITT Patient Population Reaching & Maintaining Mean Urinar |
|
| August 28, 2018 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., August 28, 2018 — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awar |
|
| August 28, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Num |
|
| August 27, 2018 |
SBBP / Strongbridge Biopharma plc / CAXTON CORP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Strongbridge Biopharma plc (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G85347105 (CUSIP Number) Mr. Heath N. Weisberg Caxton Corporation 731 Alexander Road, Bldg. 2, Suite 500 Princeton, New Jersey 08540 (212) 205-6805 (Name, Addres |
|
| August 16, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Num |
|
| August 16, 2018 |
Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares Exhibit 99.1 Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares DUBLIN, Ireland and TREVOSE, Pa., August 15, 2018 — Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has terminated the public offering of ordinary shares previously announced on August 14, 2018. The termination results from an assessment by the Company’s management t |
|
| August 15, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| August 8, 2018 |
Exhibit 99.2 Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEVÔ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome ~ SONICS Study Met Primary Endpoint with RECORLEV Demonstrating a Statistically Significant Normalization Rate of Urinary Free Cortisol at Six Months ~ ~ Key Secondary Endpoints Evaluating Cardiovascular |
|
| August 8, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update ~ Statistically Significant Positive Top-line Clinical Results Reported from SONICS Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome ~ ~ Rare Endocrine Franchise Expands with the U.S. Launch of MACRILENÔ (macimorelin) for the Diagnosis of Adult Growth Ho |
|
| August 8, 2018 |
Strongbridge Biopharma plc August 2018 Exhibit 99.3 Strongbridge Biopharma plc August 2018 Forward-looking statements This document contains forward-looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company’s future financial posit |
|
| August 8, 2018 |
SBBP / Strongbridge Biopharma plc 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 |
|
| August 8, 2018 |
CONFIDENTIAL TREATMENT REQUESTED UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 2 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 2 TO TERM LOAN AGREEMENT, |
|
| June 22, 2018 |
SBBP / Strongbridge Biopharma plc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 STRONGBRIDGE BIOPHARMA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G85347105 (CUSIP Number) June 12, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| June 11, 2018 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 31, 2018 |
SBBP / Strongbridge Biopharma plc S-8 As filed with the Securities and Exchange Commission on May 31, 2018 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 17, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number |
|
| May 10, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Reports First Quarter 2018 Financial Results and Provides Corporate Update ~ KEVEYIS® (dichlorphenamide) First Quarter 2018 Revenue of $3.9 Million ~ ~ Increased Full-Year 2018 Revenue Guidance for KEVEYIS from $16 to $19 Million to $18 to $20 Million ~ ~ MACRILEN™ (macimorelin) Product Launch on Track for July 2018 ~ ~ Development Program for RECORLEV™ (lev |
|
| May 10, 2018 |
SBBP / Strongbridge Biopharma plc 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 001-37569 |
|
| May 3, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Number) |
|
| May 3, 2018 |
Strongbridge Biopharma plc Announces New Employment Inducement Awards Exhibit 99.1 Strongbridge Biopharma plc Announces New Employment Inducement Awards Dublin, Ireland and Trevose, Pa., May 3, 2018 — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has approved inducement equity awards t |
|
| April 13, 2018 |
SBBP / Strongbridge Biopharma plc DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 27, 2018 |
SBBP / Strongbridge Biopharma plc CORRESP 900 Northbrook Drive Suite 200 Trevose, PA 19053 (610) 254-9022 March 27, 2018 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| March 27, 2018 |
SBBP / Strongbridge Biopharma plc CORRESP 900 Northbrook Drive Suite 200 Trevose, PA 19053 (610) 254-9022 March 27, 2018 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| March 22, 2018 |
SBBP / Strongbridge Biopharma plc S-3/A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on March 22, 2018. |
|
| March 22, 2018 |
SBBP / Strongbridge Biopharma plc CORRESP 599 Lexington Avenue New York, NY 10022-7650 Tel +1 212 521 5400 Fax +1 212 521 5450 reedsmith. |
|
| March 12, 2018 |
Registration Statement on Form S-3 (No. 333-223576), filed with the SEC on March 12, 2018; Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on March 12, 2018. |
|
| March 12, 2018 |
Form S-3 (No. 333-223575), filed with the SEC on March 12, 2018 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on March 12, 2018. |
|
| March 12, 2018 |
SBBP / Strongbridge Biopharma plc POS AM As filed with the Securities and Exchange Commission on March 12, 2018 Registration No. |
|
| March 12, 2018 |
SBBP / Strongbridge Biopharma plc POS AM As filed with the Securities and Exchange Commission on March 12, 2018 Registration No. |
|
| March 12, 2018 |
SBBP / Strongbridge Biopharma plc 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2018 STRONGBRIDGE BIOPHARMA plc (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of incorporation) 001-37569 (Commission File Numb |
|
| March 12, 2018 |
Exhibit 99.1 Strongbridge Biopharma plc Reports Full-Year 2017 Financial Results ~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~ ~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~ ~ MACRILEN™ (macimorelin) Product Launch on Track for Mid-2018 ~ ~ RECORLEV™ (levoketoconazole) Phase 3 Clinical Program Progressing |
|
| March 12, 2018 |
Exhibit 10.20 STRONGBRIDGE BIOPHARMA plc 2017 INDUCEMENT PLAN STOCK OPTION AWARD Strongbridge Biopharma plc (the “Company”) has granted you a Stock Option (the “Option”) under the 2017 Inducement Plan (the “Plan”). The terms of the grant are set forth in the Stock Option Award Agreement provided to you (the “Agreement”). The following provides a summary of the key terms of the grant; however, you |
|
| March 12, 2018 |
Exhibit 21.1 Subsidiaries of the Company Strongbridge U.S. Inc. (a Delaware corporation) Strongbridge Ireland Limited (a private limited company incorporated under the laws of Ireland) Cortendo AB (publ) (a public limited liability company incorporated under the laws of Sweden) Cortendo Cayman Ltd. (an exempted company incorporated in the Cayman Islands) |
|
| March 12, 2018 |
EXHIBIT 10.29 CONFIDENTIAL TREATMENT REQUESTED UNDER C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406. [****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. EXECUTION VERSION AMENDMENT 1 TO TERM LOAN AGREEMENT THIS AMENDMENT 1 TO TERM LOAN AGREEMENT, dated a |
|
| March 12, 2018 |
Exhibit 10.16 STRONGBRIDGE BIOPHARMA PLC 2015 EQUITY COMPENSATION PLAN INCENTIVE STOCK OPTION AWARD Strongbridge Biopharma plc (the “Company”) has granted you an Incentive Stock Option (the “Option”) under the 2015 Equity Compensation Plan (the “Plan”). The terms of the grant are set forth in the Incentive Stock Option Award Agreement provided to you (the “Agreement”). The following provides a sum |
|
| March 12, 2018 |
EXHIBIT 10.21 STRONGBRIDGE BIOPHARMA PLC 2017 INDUCEMENT PLAN RESTRICTED STOCK UNIT AWARD Strongbridge Biopharma plc (the “Company”) has determined to grant to you an award of restricted stock units (the “RSUs”) under the 2017 Inducement Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). The following provides a summary |
|
| March 12, 2018 |
EXHIBIT 10.30 Exhibit I to Term Loan Agreement FORM OF WARRANT THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN AC |
|
| March 12, 2018 |
EXHIBIT 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made by and between Strongbridge U.S. Inc., a Delaware corporation (the “Company”), and (“Executive”) as of October 13, 2017. W I T N E S S E T H: WHEREAS, the Company and Executive are parties to an amended and restated employment agreement (such agreement, the “Prior Agreeme |
|
| March 12, 2018 |
Strongbridge Biopharma plc Non-Employee Director Equity Compensation Plan Exhibit 10.14 STRONGBRIDGE BIOPHARMA PLC NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION PLAN The purpose of the Strongbridge Biopharma plc Non-Employee Director Equity Compensation Plan (the “Plan”) is to provide non-employee members of the Board of Directors (the “Board”) of Strongbridge Biopharma plc (the “Company”) with the opportunity to receive grants of nonqualified stock options and stock awards |
|
| March 12, 2018 |
SBBP / Strongbridge Biopharma plc 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| March 12, 2018 |
Exhibit 10.17 STRONGBRIDGE BIOPHARMA PLC 2015 EQUITY COMPENSATION PLAN NONQUALIFIED STOCK OPTION AWARD Strongbridge Biopharma plc (the “Company”) has granted you a Nonqualified Stock Option (the “Option”) under the 2015 Equity Compensation Plan (the “Plan”). The terms of the grant are set forth in the Nonqualified Stock Option Award Agreement provided to you (the “Agreement”). The following provid |
|
| March 12, 2018 |
Exhibit 10.18 STRONGBRIDGE BIOPHARMA PLC 2015 EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD Strongbridge Biopharma plc (the “Company”) has determined to grant to you an award of restricted stock units (the “RSUs”) under the 2015 Equity Compensation Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). The following p |
